reports
Important Advances in Oxurion's R&D Program on Geographic Atrophy seco...
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD ` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD). This recently launched program has reached the first step with the identification of 50 targets that have the potent...
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 03/05/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 05/03/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Damien Choplain
- Martial Descoutures
Galapagos : Largely unsurprising numbers
>Solid cash position - Galapagos reported its Q1 earnings after the close in the US. Group revenues came in at € 100m vs € 83m expected. The bulk stemmed from its agreement with Gilead for € 62m while net product sales amounted to € 37m. At the operating level, costs were broadly under control, with total expenditure of around € 129m vs € 110m although we note an increase of close to 36% in R&D expense due to the development of the clinical portfolio. In contrast...
- Damien Choplain
- Martial Descoutures
Galapagos : Une publication sans grande surprise
>Une trésorerie solide - Galapagos publiait après la fermeture du marché US ses résultats du T1. Les revenus du groupe ressortent ainsi à 100 M€ vs 83 M€ att. L’essentiel des revenus vient de son accord avec Gilead pour 62 M€ alors que les ventes des produits nets ressortent à 37 M€. Au niveau opérationnel, les coûts sont globalement bien maitrisés ce qui conduit à avoir des dépenses totales de l’ordre de 129 M€ vs 110 M€ même si nous observons une hausse de près...
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Sharad Kumar S.P
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Galapagos FIRST LOOK: uneventful 1Q24 results, FY24 cash burn guidance...
Galapagos reported uneventful 1Q24 results and confirmed its FY24 cash burn guidance of € 280-320m (FY23: € 414.8m), thanks to the savings from the transfer of Jyseleca to Alfasigma. While the company did not provide an update on timelines for its pipeline, we think data updates from the phase 1/2 CAR-T trials in r/r NHL and r/r CLL could come at upcoming scientific conferences (e.g. ASH in December 2024). Beyond that, BD remains on the table and we'd like to see an acceleration on that front wi...
- David Seynnaeve
- PhD
Galapagos - Q1 24 results
GLPG published its Q1 results, reporting Group net revenues of EUR 100m, in line with CSS. Net profit was significantly up (but below CSS), notably boosted by preliminary calculation of the gain on the sale of Jyseleca.FY24 reduced cash burn guidance reiterated. Nothing new on the CAR-T front. Yet, it is good to see that the company still plans to submit IND applications for its CAR-Ts still in 2024. Remember that GLPG has been running CAR-T trials in Europe only so far.Overall, no material surp...
Galapagos reports first quarter 2024 financial results
Galapagos reports first quarter 2024 financial results Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 2024Reconfirmed 2024 cash burni guidance o...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2024 Vooruitgang met potentiële best-in-class R&D pijplijn van celtherapie en kleine moleculen, met vier klinische assets en >15 onderzoeksprogramma's in oncologie en immunologie Overeenkomsten afgesloten met BridGene Biosciences en Thermo Fisher Scientific, en investering in Frontier MedicinesJyseleca® business overgedragen aan Alfasigma S.p.A., waardoor middelen vrijkomen om te investeren in groeigebiedenNetto groepsomzet in het eerste kwartaal van €100 miljoenGeldmiddelen en kortlopende financiële investeringen van €...
- Javier Esteban
ING GROEP: RDOS. 1T’24 (ANÁLISIS BANCO SABADELL)
Rdos. 1T'24 vs 1T'23: M. Intereses: 3.825 M euros (-4,7% vs -3,7% BS(e) y -4,2% consenso); M. Bruto: 5.583 M euros (+0,3% vs -2,4% BS(e) y -2,3% consenso); M. Neto: 2.551 M euros (+2,2% vs -6,7% BS(e) y -6,2% consenso); BDI: 1.578 M euros (-0,8% vs -9,5% BS(e) y -11,2% consenso). Rdos. 1T'24 vs 4T'23: M. Intereses: 3.825 M euros (-1,3% vs -0,3% BS(e) y -0,8% consenso); M. Bruto: 5.583 M euros (+3,2% vs +0,5% BS(e) y +0,5% consenso); M. Neto: 2.551 M euros (+9,4% vs -0,2% BS(e) y +0,4% consenso);...
- Research Department
INFORME DIARIO 02 MAYO + RDOS. ESPAÑA Y EUROPA 1T’24. IDEAS DESTACADAS...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: AENA, ARCELORMITTAL, METROVACESA, REDEIA. EUROPA: AIRBUS, ING. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’24 que se publicarán en España y Europa en los próximos días. El Ibex pierde otra vez los 11.000 puntos Jornada de caídas en las bolsas europeas previo a la reunión de la Fed donde el Ibex volvió...
Galapagos’ shareholders adopt all resolutions proposed by the Board of...
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024 Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 30 April 2024 were approved. The AGM approved, amongst other items: The Remuneration Report and revised Remuneration PolicyThe remuneration of the members of the Board of DirectorsThe reappointment of Dr. Elisabeth Svanberg as Independent...
Galapagos’ aandeelhouders keuren alle door de Raad van Bestuur voorges...
Galapagos’ aandeelhouders keuren alle door de Raad van Bestuur voorgestelde besluiten goed op de jaarlijkse Gewone en Buitengewone Algemene Aandeelhoudersvergaderingen 2024 Mechelen, België; 30 april 2024; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) maakt vandaag bekend dat alle voorstellen tot besluit op de jaarlijkse Gewone en Buitengewone Algemene Aandeelhoudersvergaderingen van 30 april 2024 zijn goedgekeurd. De jaarlijkse Gewone Algemene Aandeelhoudersvergadering keurde onder meer goed: Het Remuneratieverslag en gewijzigde RemuneratiebeleidDe bezoldiging van de BestuurdersDe he...
Euronext upgraded to ‘BBB+, Positive Outlook‘ by S&P
Euronext upgraded to ‘BBB+, Positive Outlook‘ by S&P Contacts Media Contact Investor Relations Amsterdam Brussels 27 Dublin 13 Lisbon 4 Milan 12 Oslo Paris 45 Euronext upgraded to ‘BBB+, Positive Outlook‘ by S&P Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 30 April 2024 – Euronext, the leading pan-European market infrastructure, today welcomes the decision of S&P to upgrade Euronext from ‘BBB+, Stable Outlook’ to ‘BBB+, Positive Outlook’. S&P decision reflects the approaching completion of the integration of the Borsa Italia...
- Jørgen Lian
Yard response and dry bulk qualms
Our trip to South Korea and China revealed Chinese shipbuilders are seeking growth to take on Korea’s established yards who are facing constraints. An eagerness to add capacity is one of our takeaways, as well as a gloomy outlook for Chinese real estate, which in our view should inevitably weigh on dry bulk demand.
DHT DHT HOLDINGS INC.
SBL SAFE BULKERS INC.
LPG DORIAN LPG
GNK GENCO SHIPPING & TRADING LTD.
MAERSK B A.P. MOLLER - MAERSK A/S CLASS B
ODF ODFJELL ASA
WAWI WALLENIUS WILHELMSEN LOGISTICS ASA
WWI WILHELM WILHELMSEN HOLDING
SBLK STAR BULK CARRIERS CORP.
FRO FRONTLINE LTD.
G2O GOLAR LNG LIMITED
AMSC AMERICAN SHIPPING COMPANY ASA
SN6 STOLT-NIELSEN LTD.
BWLPG BW LPG LTD.
GOGLO GOLDEN OCEAN GROUP LTD
AVACF AVANCE GAS HOLDINGS LTD
HUNT HUNTER GROUP ASA
STNG SCORPIO TANKERS INC.
FLNG FLEX LNG LTD.
SFL SFL CORPORATION LIMITED
TNK TEEKAY TANKERS
2020 2020 BULKERS LTD
KCC KLAVENESS COMBINATION CARRIERS
EGLE EAGLE BULK SHIPPING
MPCC MPC CONTAINER SHIPS AS
HAUTO HOEGH AUTOLINERS ASA
WEST WESTERN BULK CHARTERING
HAFNI HAFNIA
COOL COOL COMPANY LTD.
HSHP HIMALAYA SHIPPING LTD.
- Lynn Hautekeete
Qrf City Retail Catalysts not translated in share price reaction
We update our model after the 1Q24 results and take into account the exit from the Dutch market, JV closing and non-strategic asset sales announced in 1Q24. We believe the stock price did not react enough to the positive catalyst of the Dutch sales and JV closing at 15.13% IRR. Hence, we repeat our BUY recommendation and EUR 13.0 TP. Standing asset valuations increased with 1.3% in 1Q24 signalling the revival of retail real estate. This is also reflected in the record high occupancy rate at 99....
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 25, 2024, from Atlas Special Opportunities, LLC indicating that as of April 19, 2024, it held 380,755,774 shares of the then o...
- Guy Sips
- Kristof Samoy
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
Publication Annual Report – Annual Shareholders' Meeting
Publication Annual Report – Annual Shareholders' Meeting Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The annual report for the year ending December 31, 2023 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF. On this day as well, the Company has convened its Annual Shareholders' Meeting. The relevant documents pertaining to...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.